CorMedix Q3 Revenue $54.5M Beats Consensus; Suspends 2027 DefenCath Guidance on CMS Changes
CRMD is trading near its 52-week low of $5.1 (2.9% above the low).
Summary
CorMedix beat Q3 revenue consensus with $54.5 million and kept FY2026 guidance, but suspended 2027 DefenCath guidance citing CMS reimbursement changes, leaving the post-TDAPA pricing outlook unclear.
Key Events · Earnings and Guidance · CRMD
-
Q3 Revenue Beats Consensus
Consolidated revenue of $54.5 million topped the $51.2 million street consensus, though it fell from $104.3 million a year earlier on post-TDAPA DefenCath pricing.
-
DefenCath Sales Rely on Estimate Change
DefenCath contributed $17.2 million of net revenue, including a $5.0 million favorable change in estimate related to sales allowances; the rest of the portfolio added $37.3 million.
-
Net Loss Driven by Non-Cash Item
The $14.7 million net loss, or $(0.19) per share, included an $11.5 million non-cash remeasurement of Melinta contingent consideration; adjusted EBITDA was $3.1 million.
-
2027 DefenCath Guidance Suspended
Management suspended previously issued 2027 DefenCath revenue guidance and deferred future guidance to early 2027, citing CMS reimbursement framework changes and limited visibility on utilization and pricing.
Analysis · CRMD · Life Sciences
The revenue beat is real, but the quarter's quality is mixed. DefenCath sales of $17.2 million leaned on a $5.0 million favorable change in sales-allowance estimate, and the $14.7 million net loss was driven by an $11.5 million non-cash remeasurement of Melinta contingent consideration — an accounting entry, not cash leaving the business. Guidance is the bigger story: FY2026 revenue is held at $325-$345 million and adjusted EBITDA narrowed to $130-$140 million, yet management suspended all 2027 DefenCath guidance because of CMS reimbursement changes, removing visibility on the franchise that just took a post-TDAPA pricing hit. Against that, $355.2 million of cash plus a $150 million non-dilutive term loan (about $75 million drawn at the Heron closing) funds the acquisition without new share issuance.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRMD was trading at $5.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $413.1M. The 52-week trading range was $5.10 to $13.02. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.